

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 7, 2025

CD8a Monoclonal Antibody (53-6.7), PerCP-Cyanine5.5, eBioscience

RRID:AB_1107004

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 45-0081-82, RRID:AB_1107004)

Antibody Information

URL: http://antibodyregistry.org/AB_1107004

Proper Citation: (Thermo Fisher Scientific Cat# 45-0081-82, RRID:AB_1107004)

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow (0.25 µg/test)
Consolidation on 1/2020: AB_1107004, AB_10335677

Antibody Name: CD8a Monoclonal Antibody (53-6.7), PerCP-Cyanine5.5, eBioscience

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: Clone 53-6.7

Antibody ID: AB_1107004

Vendor: Thermo Fisher Scientific

Catalog Number: 45-0081-82

Record Creation Time: 20231110T074312+0000

Record Last Update: 20241115T010636+0000

Ratings and Alerts

No rating or validation information has been found for CD8a Monoclonal Antibody (53-6.7), PerCP-Cyanine5.5, eBioscience.

No alerts have been found for CD8a Monoclonal Antibody (53-6.7), PerCP-Cyanine5.5, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Kwon DI, et al. (2024) Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells. *Cell reports. Medicine*, 5(1), 101362.

Fu X, et al. (2024) Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis. *British journal of cancer*, 130(5), 716.

Abadie K, et al. (2024) Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision. *Immunity*, 57(2), 271.

Luo Z, et al. (2024) Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment. *Cell reports*, 43(9), 114697.

Liu C, et al. (2024) A CTCF-binding site in the Mdm1-Il22-Ifng locus shapes cytokine expression profiles and plays a critical role in early Th1 cell fate specification. *Immunity*, 57(5), 1005.

Denny JE, et al. (2024) Monoclonal antibody-mediated neutralization of *Clostridioides difficile* toxin does not diminish induction of the protective innate immune response to infection. *Anaerobe*, 88, 102859.

Fukushima H, et al. (2024) Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells. *EBioMedicine*, 102, 105050.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. *Cell reports. Medicine*, 5(5), 101567.

Wu Q, et al. (2024) Ferritin heavy chain supports stability and function of the regulatory T cell lineage. *The EMBO journal*, 43(8), 1445.

Marx AF, et al. (2023) The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection. *Immunity*, 56(4), 813.

Mandarano AH, et al. (2023) DRAK2 contributes to type 1 diabetes by negatively regulating IL-2 sensitivity to alter regulatory T cell development. *Cell reports*, 42(2), 112106.

Mise-Omata S, et al. (2023) SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine. *Cell reports*, 42(8), 112940.

Xie J, et al. (2023) The miR-17-92 miRNAs promote plasma cell differentiation by suppressing SOCS3-mediated NIK degradation. *Cell reports*, 42(8), 112968.

Xu Z, et al. (2023) PTEN regulates hematopoietic lineage plasticity via PU.1-dependent chromatin accessibility. *Cell reports*, 42(8), 112967.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. *Cancer cell*, 41(2), 235.

Zhou X, et al. (2023) MHC class II regulation of CD8+ T cell tolerance and implications in autoimmunity and cancer immunotherapy. *Cell reports*, 42(11), 113452.

Liedmann S, et al. (2022) Localization of a TORC1-eIF4F translation complex during CD8+ T cell activation drives divergent cell fate. *Molecular cell*, 82(13), 2401.

Liu H, et al. (2022) Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity. *Cell reports. Medicine*, 3(6), 100660.

Ruan GX, et al. (2022) The spliceosome component Usp39 controls B cell development by regulating immunoglobulin gene rearrangement. *Cell reports*, 38(6), 110338.

Ramos S, et al. (2022) A hypometabolic defense strategy against malaria. *Cell metabolism*, 34(8), 1183.